Interestingly, in rats with DMBA-induced mammary cancer, fucoidan (200 and 400 mg/kg, p.o., 4 months of treatment) also presented an immunomodulatory effect through the programmed death-1/programmed death-ligand-1 (PD1/PDL1) pathway. The gene discussed is CD274; the disease is breast cancer.